top of page

業績（2019年）

Publications

  1. Kato T, Yamada A, Sasa K, Yoshimura K, Morimura N, Ogata H, Sakashita A, Kamijo R. Nephronectin Expression is Inhibited by Inorganic Phosphate in Osteoblasts. Calcif Tissue Int. 2019 Feb;104(2):201-206. doi: 10.1007/s00223-018-0484-3. PMID: 30341591

  2. Yogo T, Tsukada N, Nashimoto J, Uto Y, Sato K, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Okazuka K, Ishida T, Suzuki K. Efficacy of plerixafor in autologous peripheral blood stem cell collection. Rinsho Ketsueki.2019;60(3):165-170. Japanese. doi: 10.11406/rinketsu.60.165. PMID: 31068511

  3. Hattori N, Nakamaki T. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Int J Mol Sci. 2019 Apr 26; 20(9):2057. doi: 10.3390/ijms20092057. PMID: 31027331

  4. Aizawa R, Yamada A, Seki T, Tanaka J, Nagahama R, Ikehata M, Kato T, Sakashita A, Ogata H, Chikazu D, Maki K, Mishima K, Yamamoto M, Kamijo R.Cdc42 regulates cranial suture morphogenesis and ossification.Biochem Biophys Res Commun. 2019 Apr 30;512(2):145-149. doi: 10.1016/j.bbrc.2019.02.106. PMID: 30853186

  5. Arai N, Homma M, Abe M, Baba Y, Murai S, Watanuki M, Kawaguchi Y, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Saito B, Shiozawa E, Harada H, Yamochi-Onizuka T, Nakamaki T, Takimoto M. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia. Int J Hematol. 2019 May; 109(5): 539-544. doi: 10.1007/s12185-019-02616-y. PMID: 30847774

  6. Lao ZT, Ding LW, An O, Hattori N, Sun QY, Tan KT, Mayakonda A, Chuan WG, Madan V, Lin DC, Yang H, Koeffler HP. Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. Haematologica. 2019 May;104(5): e200-e203. doi: 10.3324/haematol.2018.202911. PMID: 30514800

  7. Nishio Y, Sakai H, Saiki Y, Uchida A, Uemura Y, Matsunawa M, Isobe Y, Kato M, Tomita N, Miura I. Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele. Int J Hematol. 2019 May;109(5):572-577. doi: 10.1007/s12185-019-02629-7. PMID: 30887274

  8. Baba Y, Saito B, Shimada S, Sasaki Y, Murai S, Abe M, Fujiwara S, Arai N, Kawaguchi Y, Kabasawa N, Tsukamoto H, Uto Y, Yanagisawa K, Hattori N, Harada H, Nakamaki T. Development of cardiac tamponade and emergence of arrhythmia during chemotherapy for diffuse large B-cell lymphoma. Rinsho Ketsueki. 2019; 60(6): 577-581. Japanese. doi: 10.11406/rinketsu.60.577.　PMID: 31281147

  9. Yogo T, Okazuka K, Nashimoto J, Uto Y, Sato K, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Tsukada N, Ishida T, Suzuki K. Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis.  Int J Hematol. 2019 Oct;110(4):431-437. doi: 10.1007/s12185-019-02692-0. PMID: 31236823

  10. Fujiwara S, Hattori N, Matsui T, Nakata A, Sasaki Y, Shimada S, Murai S, Abe M, Baba Y, Watanuki M, Kawaguchi Y, Arai N, Kabasawa N, Tsukamoto H, Uto Y, Yanagisawa K, Harada H, Nakamaki T. Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation. Transplant Proc. 2019 Dec;51(10):3437-3443.  doi: 10.1016/j.transproceed.2019.08.044.PMID: 31733801

  11. Sato K, Tsukada N, Nashimoto J, Uto Y, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Okazuka K, Ishida T, Suzuki K.  Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation. Rinsho Ketsueki.  2019;60(12):1635-1640. Japanese. doi: 10.11406/rinketsu.60.1635. PMID: 31902813

bottom of page